Recent Highlights and Anticipated Milestones: Metabolic Dysfunction-Associated Steatohepatitis (MASH) (GlobeNewswire) - Nov 6, 2025 - "End-of-Phase 2 Meeting with FDA scheduled for fourth quarter 2025: During the in-person meeting, the Company is seeking alignment with the Agency on its proposed Phase 3 trial design and study endpoints; 48-week data from Phase 2b IMPACT Trial to be reported in fourth quarter 2025: The readout will include longer-term NIT and weight loss data."
FDA event • P2b data • Metabolic Dysfunction-Associated Steatohepatitis
|